Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
renal cell carcinoma
Biotech
Instil Bio takes the ax to its lead asset, cuts 60% of its staff
Instil Bio is trekking through rocky terrain, culling its lead asset and cutting 60% of its staff as it tries to instill confidence in a new path.
Max Bayer
Dec 8, 2022 10:24am
FDA sinks Allarity’s plans for lead oncology asset
Aug 2, 2022 2:41pm
Despite 0% response rate, 4D hits primary goal in cancer trial
Mar 23, 2022 7:45am
FDA allows Allogene to resume CAR-T trials after safety scare
Jan 10, 2022 10:16am
Chasing Merck, Arrowhead posts early data on anti-cancer RNAi
Jul 7, 2021 9:00am
Calithera flunks phase 2 cancer trial, axes 35% of staff
Jan 4, 2021 8:23am
